Home > Dosing & Administration: Dose Modifications

TAZVERIK® (tazemetostat) OFFERS ORAL TWICE‑DAILY DOSING AND CAN BE TAKEN WITH OR WITHOUT FOOD1

Dose Reduction
Dosage
First
Dosage:
600 mg twice daily
Second
Dosage:
400 mg twice daily*

*Permanently discontinue TAZVERIK in patients who are unable to tolerate 400 mg orally twice daily.1

Neutropenia
Severity
Neutrophil count less than 1 x 109/L
Dosage Modification
  • Withhold until neutrophil count is greater than or equal to 1 × 109/L or baseline.
  • For first occurrence, resume at same dose.
  • For second and third occurrence, resume at reduced dose.
  • Permanently discontinue after fourth occurrence.
Thrombocytopenia
Severity
Platelet count less than 50 x 109/L
Doseage Modification
  • Withhold until platelet count is greater than or equal to 75 × 109/L or baseline.
  • For first and second occurrence, resume at reduced dose.
  • Permanently discontinue after third occurrence.
Anemia
Severity
Hemoglobin less than 8 g/dL
Dosage Modification
  • Withhold until improvement to at least Grade 1 or baseline, then resume at same or reduced dose.
Other adverse reactions
Severity
Grade 3
Dosage Modification
  • Withhold until improvement to at least Grade 1 or baseline.
  • For first and second occurrence, resume at reduced dose.
  • Permanently discontinue after third occurrence.
Severity
Grade 4
Dosage Modification
  • Withhold until improvement to at least Grade 1 or baseline.
  • For first occurrence, resume at reduced dose.
  • Permanently discontinue after second occurrence.
Review the Select Lab Abnormalities table when considering dose modifications for adverse reactions

Recommended dose reductions of TAZVERIK for moderate CYP3A inhibitors1

Current Dosage:
800 mg orally twice daily
Adjusted Dosage:
400 mg orally twice daily
Current Dosage:
600 mg orally twice daily
Adjusted Dosage:
400 mg for the first dose and 200 mg for second dose
Current Dosage:
400 mg orally twice daily
Adjusted Dosage:
200 mg orally twice daily

Dose adjustments are not recommended for patients with:

  • mild to severe renal impairment, including end-stage renal disease.1
  • mild hepatic impairment. TAZVERIK has not been studied in patients with moderate or severe hepatic impairment.1†

† Mild=total bilirubin > 1 to 1.5 times ULN or AST > ULN; moderate=total bilirubin > 1.5 to 3 times ULN; severe=total bilirubin > 3 times ULN.1

CYP3A=Cytochrome P450 (CYP)3A; AST=aspartate aminotransferase; ULN=upper limit of normal.

Reference: 1. TAZVERIK (tazemetostat) Prescribing Information. Cambridge, MA: Epizyme, Inc., July 2020.